Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesy...

Description complète

Détails bibliographiques

Auteurs principaux:	Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2018-09-01
Collection:	Cancer Medicine
Sujets:	eribulin metastatic breast cancer real‐world survival triple negative
Accès en ligne:	https://doi.org/10.1002/cam4.1705
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!